Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Animalcare Group Plc | ANCR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 219.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 219.00 | 219.00 | 219.00 | 219.00 |
| Industry Sector |
|---|
| FOOD PRODUCERS |
| Top Posts |
|---|
Posted at 23/3/2025 10:48 by simon gordon Oliver Shah - 23/3/25:Aim has that sinking feeling Last October, I wondered where the Aim investors’ yachts were. At that point, the junior market had lost a quarter of its value since its birth in 1995. I remarked that it had been a rather more lucrative affair for brokers than shareholders. Now it appears that even the brokers may have to sell their yachts. The market has fallen further — by more than 30 per cent. The Tony Blair Institute and the think-tank Onward have recommended dissolving Aim entirely as part of efforts to revive the main bourse. A well-known fund manager suggests a twist on this idea: move the top 100 Aim companies, which account for the lion’s share, onto the main market — and delist the rest. |
Posted at 23/3/2025 10:34 by simon gordon Danny Forston - 22/3/25:Pill to make dogs live longer may be here in a year. Are we next? The US biotech firm Loyal has raised £115 million to develop a drug to give our pets an extra year of healthy life. One day, says its boss, we’ll all want to try it A San Francisco biotech start-up called Loyal is working on a radical plan to give dogs and their owners more time together with a once-a-day pill that promises to give most dogs at least another year of healthy life. Last month, Loyal received key approval from the US regulator, the Food and Drug Administration (FDA), for what would be the world’s first drug specifically aimed at life extension. Loyal, which has just raised an extra $22 million (£17 million) to bring its backing to $150 million (£115 million), is in the vanguard of a Silicon Valley longevity craze. At its heart is a subtle but fundamental shift among scientists: increasingly, ageing itself — and not just the many ailments that come along with it — is seen as a condition to be treated. Numerous life extension start-ups have raised billions of dollars from investors such as Jeff Bezos, the boss of Amazon, and Brian Armstrong, who founded the cryptocurrency platform Coinbase. Loyal is not alone. Elanco, a listed $5 billion animal health company, last week announced rival research into life-extension treatments for dogs. The company explained: “Shifting pet ownership to younger generations and the increased time spent with pets during Covid have increased both pet owners’ expectation of care and willingness to spend to protect pet health.” Loyal’s pill mimics the metabolic benefits that come from “caloric restriction”, or fasting, which is one of the most well-established approaches to life extension. When the body operates on fewer calories, it metabolises fuel more efficiently. Yet few are willing to go through the suffering involved in eating much less. As dogs — and humans — age, metabolic fitness degrades, with effects ranging from weight gain and insulin resistance to loss of muscle mass. What Loyal’s approach is not, Halioua is quick to point out, is an appetite suppressant along the lines of the blockbuster human drugs Wegovy or Ozempic, to treat weight loss and diabetes. “The idea is: can we emulate the benefits of caloric restriction and its beneficial impacts on metabolic fitness, but without suppressing appetite? Because nobody wants an appetite suppressant for their dog,” Halioua said. “Everyone asks me, ‘Is this just Ozempic for dogs?’ And the answer is no.” |
Posted at 19/3/2025 21:03 by simon gordon An article to rage about the state of UK capital markets and the horrifically incompetent leadership of the economy....Michael Tory - 20/1/25: A Novel Fiscal Fix for What Ails the UK Economy Allocating some of the additional tax revenue raised by the budget to the state-owned pension fund could generate future economic growth. A single chart captures much of what has been wrong with British economic policy over the past two decades and is, sadly, a perfect illustration of this country’s seemingly inexorable economic decline, of which the latest market crisis is merely a further symptom. But there’s a way to begin breaking the cycle. The chart shows the steady downward trend — some 30% since 2001 — in the UK stock market’s value relative to its gross domestic product; the same measure for its global peers over the same period increased by more than 50%. Had the UK merely kept pace with the average, the UK stock market’s value today would be more than double its current level – £5.5 trillion ($6.7 trillion) versus £2.5 trillion – and today we’d be in the top five globally rather than outside the top 10. This decline — unmatched in a Group of Seven economy — has two main components, which are in turn derived from the UK’s chronic lack of domestic savings and investment. First, triggered by policy mistakes in the early 2000s, UK pension funds and insurers steadily liquidated their holdings in listed UK companies. This prompted an unprecedented yard sale of great UK companies, investments that had been built over generations being abandoned by their natural long-term owners. The remaining listed companies are, with limited exceptions, now in “harvest” The second component is even more profound and unjust as its effect is infinite: The missing accumulation of value that should naturally accrue to domestic investors and savers from the UK’s bountiful new business formation, which spans a wide spectrum of dynamic sectors such as life sciences, artificial intelligence, robotics, materials science, aerospace and defense and the creative industries. However, virtually all new wealth creation from this country’s innovations and startups is now captured by foreign capital. Take two examples: ARM Holdings Plc, which departed these shores in 2016 valued at around $32 billion, and pioneering AI startup DeepMind. ARM is today listed on the US Nasdaq exchange with a market value of $155 billion. DeepMind was acquired by Alphabet Inc. a decade ago to form the core of its AI division; AI has in turn helped drive Alphabet’s valuation to $2 trillion. Even if only, say, 10% is attributable to AI, this $200 billion compares with the $400 million Alphabet is reported to have paid for DeepMind in 2014. So just two companies have effectively cost British savers and investors more than $300 billion in lost value. This has repercussions for the current malaise afflicting gilts and the pound. Britain’s dismal growth record and outlook matter more than its current fiscal position. UK per capita income has been more or less stagnant since 2007. Since economic growth is the most important variable for future tax revenue, according to the Office for Budget Responsibility, confidence in the outlook drives expectations for the fiscal position, and hence the government’s borrowing requirement and the clearing rate of interest to fund it. So it’s no surprise that a budget that both increased taxes on business and reduced after-tax returns on new investment would reduce expectations for GDP — with a corresponding downgrade of future tax income that swamped the amounts raised by the budget measures. The UK is trapped in a recursive loop: A gloomy growth outlook diminishes expectations for fiscal revenue, driving up borrowing costs and prompting speculation about … future tax increases. There’s a partial solution available. Having decided to increase levies on business by increasing National Insurance contributions, half of that additional revenue — £12 billion, say — should be allocated for investment and management by the Pension Protection Fund (PPF). The PPF is a state-owned asset pool with an infinite time horizon that’s generated average annual returns since 2006 of around 8%. The mandate would be clear: 75% of the fund’s assets would be allocated to domestic equity investment to begin restoring lost risk capital for infrastructure, mid-sized companies seeking global scale, investment in smaller listed companies and emerging technologies firms. By initially raiding the fiscal purse, the government could generate future economic expansion that would in turn bolster long-term tax revenue. This bold, course-correcting change would deliver lasting benefits: a sustainable, investment-led improvement in GDP; an instant transformation of fiscal revenue into capital, breaking the confidence-sapping tax/spend cycle; and more efficient capital deployment through best-in-class professional fund management and monitoring. Most importantly, it would allow the public to once again begin to share in the wealth creation that springs from Britain’s extraordinary innovation capacity and entrepreneurial energy. |
Posted at 04/3/2025 20:19 by simon gordon Times - 4/3/25:London markets need a dose of optimism to keep them attractive No one is a bigger supporter of London’s capital markets than me. There are excellent people running finance companies and leading businesses in London. When our chairman, Andrew Brode, and I listed Learning Technologies Group (LTG) on the London Stock Exchange in 2013 we believed it was the best way to raise money to make deals. Last week, however, we both voted in favour of a takeover by the US private equity firm General Atlantic. LTG’s independent board came to the same conclusion. As a private company we will be better equipped to handle the challenges and opportunities that artificial intelligence presents with the backing of a private equity firm that understands how to help technology businesses to grow. So what does this say about the state of London’s markets? The Aim market gave LTG an exceptional platform in our first eight years as a listed company. We made 17 acquisitions to become the leading consolidator in the learning and talent development industry. This supported LTG’s growth from a hundred people and £10 million revenues in 2013 to more than five thousand people and nearly £500 million revenues today. The fact is, though, for the past three years the markets simply did not serve their purpose of raising money and valuing businesses fairly. The increasingly challenging macroeconomic backdrop has not been kind to the markets and LTG. Despite doubling profit in 2022 we lost a quarter of our value after a minor, technical balance sheet restatement. I reflected long and hard on London’s capital markets before deciding to leave. One of my conclusions is that investors disproportionately punish negative news but do not reward positive news. For instance, our share price reduced significantly because we had debt on our balance sheet as interest rates rose. By 2024 we eliminated our debt but our share price did not recover. This is not just a share price issue: it affects staff morale (many of our staff were in shareholder schemes), leadership team motivation and our ability to do deals. Ultimately this is why I left a market, Aim, that had served LTG extremely well for a long period. So what would it take for London’s markets to be attractive to entrepreneurs? I can think of three tangible fixes. First, we simply must have a stable political backdrop to breed confidence and encourage consumer spend. Second, government incentives are crucial. We need policies to encourage investors to put their money back into the stock market and boost liquidity. Third, investors and entrepreneurs need to see a continued commitment to reducing the regulatory burden on companies and markets. The new listing rules governing London’s capital markets are a good start but what about removing tax relief on risk-free cash Isas to encourage investment in AIM stocks? Structural fixes can provide a better foundation but will not change much without good old-fashioned chutzpah from business leaders and fund managers. Imagine the British adopting an American-style positive attitude (without losing our authenticity and identity) and then delivering on our stated ambitious goals. I have spent my entire business life making bold statements that I hold myself accountable to. Of course, one occasionally fails but if the environment is supportive and you learn from mistakes then everyone wins eventually. Positive thinking is infectious, empowering and enjoyable — and astonishingly easy to do, if you are so inclined. So for now LTG is pursuing value-creation with the help of a US private equity firm but I really care about London’s markets rediscovering their role as a vibrant global financial market. This is crucial for the UK economy and should mean a lot to us all. -Jonathan Satchell is chief executive of Learning Technologies Group |
Posted at 26/2/2025 11:41 by simon gordon City Am - 26/2/25:Pets at Home shares surge as watchdog set to go easy on vets The animal care retailer’s share price has been under pressure recently due to a Competition and Markets Authority probe into the veterinary sector. Investors are concerned the body will impose stricter regulations on the sector. However, Jeffries analysts have suggested that changes are “likely to be largely limited to improved transparency and regulation”, and reported increased confidence price controls will not be implemented. The CMA’s probe, which prompted over 56,000 responses from the public and vet industry, has been looking into the UK’s vet industry following concerns pet owners are not getting value for money. This included concerns that owners were being overcharged for medicine, as well as fear that consolidation by larger practices may reduce competition in the market. The investigation is key for Pets at Home, as its growth has been driven by revenue in its veterinary arm recently, with like-for-like growth of 19.9 per cent in the 12 weeks to January 2. Retail revenue fell 2.8 per cent in the same period. The most recent published papers on the probe, released by the CMA on February 6, noted concerns that customers had a limited choice of services and said that the price of vet services has risen faster than inflation. However, Jefferies analysts noted that profit margins in the sector are “largely unchanged,” adding that the CMA is unlikely to implement broad pricing control measures. “Our expert is optimistic about the outlook for the sector, believing that the trading headwinds are ‘transientR Animal care is a large and growing market – in 2022, consumers in the UK spent nearly £10bn on pet-related products, up nearly 100 per cent in a decade. Pets at Home has more than 400 surgeries across the UK. |
Posted at 21/2/2025 18:46 by simon gordon Before starting on Investor Meet in 2024 they did nothing to engage visibly with the market. Maybe they will scale up their engagement more in 2025. In the half-dead London market, you gotta go out, share the story and let peeps know why the shares are worth investing in. |
Posted at 21/2/2025 18:18 by simon gordon Held at weekly support going back to October 2024. If it does puke 220p and 200p are the next support zones.The company’s approach to marketing its shares to investors appears less than dynamic. In contrast, CNS’s CEO is highly proactive in promoting the stock, consistently engaging with investors. Meanwhile, CNC has adopted a more sophisticated strategy, employing top-tier promoters to amplify its message. Could ANCR benefit from enhancing its investor outreach? free stock charts from uk.advfn.com |
Posted at 08/2/2025 09:47 by p1nkfish What I also like is that others who are serious about animal health and building for the future (Randlab for instance) trust Animalcare as a parent rather than selling out for a bigger buck to PE. That's a form of due diligence you don't get just from institutional investors.It's one of the most interesting opportunities out there at the mo. Sensible management steering the ship well, building for the future. No advice, dyor etc, but if I was looking to add (am not as I hold quite a bundle of these at a very decent price), I would buy at 240p or below, set a stop-loss at 220p and wait for a multiple upside of capital at risk over the next 2-3 years. |
Posted at 24/1/2025 17:53 by gopher Thanks SimonThis is a very interesting acquisition and as I have said in the past the Company remains somewhat under the radar with its potential not baked into share price.Looking forward to Jenny Winters next update on investors meet platform, of course execution is everything. |
Posted at 04/12/2024 09:59 by gopher Investors champion reckons this a solid looking acquisition and I agree. I would like to see a presentation from Company but this is the major deal they have wanted to do throughout 2024. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
